Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.42
USD
|
-3.40%
|
|
-5.33%
|
-73.78%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
0.176
|
12.03
|
23.1
|
16.6
|
9.637
|
3.278
|
Enterprise Value (EV)
1 |
0.176
|
12.03
|
23.1
|
16.6
|
9.637
|
3.278
|
P/E ratio
|
-0.02
x
|
-1.58
x
|
-1.19
x
|
-0.76
x
|
-0.38
x
|
-0.14
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
6.6
x
|
59.9
x
|
204
x
|
-
|
-
|
EV / Revenue
|
-
|
6.6
x
|
59.9
x
|
204
x
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-1,270,503
x
|
-
|
-
|
EV / FCF
|
-
|
-4,138,119
x
|
-
|
-865,992
x
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-0%
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
0.98
|
237
|
425
|
1,756
|
1,780
|
2,308
|
Reference price
2 |
180.0
|
50.70
|
54.30
|
9.453
|
5.415
|
1.420
|
Announcement Date
|
3/24/20
|
3/23/21
|
3/9/22
|
3/23/23
|
2/29/24
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
-
|
1.824
|
0.3855
|
0.0815
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-13.06
|
-
|
-
|
EBIT
1 |
-
|
-2.817
|
-18.75
|
-14.03
|
-26.74
|
-32.4
|
Operating Margin
|
-
|
-154.46%
|
-4,862.73%
|
-17,206.62%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-2.958
|
-18.57
|
-14.02
|
-25.97
|
-31.68
|
Net income
1 |
-2.371
|
-2.958
|
-18.57
|
-14.02
|
-25.97
|
-31.68
|
Net margin
|
-
|
-162.21%
|
-4,817.2%
|
-17,197.51%
|
-
|
-
|
EPS
2 |
-11,775
|
-32.10
|
-45.60
|
-12.45
|
-14.29
|
-10.03
|
Free Cash Flow
|
-
|
-2.907
|
-
|
-19.16
|
-
|
-
|
FCF margin
|
-
|
-159.42%
|
-
|
-23,506.03%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/20
|
3/23/21
|
3/9/22
|
3/23/23
|
2/29/24
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.0304
|
0.165
|
0.0815
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-1.952
|
-13.74
|
-2.428
|
-2.242
|
-3.971
|
-5.388
|
-4.271
|
-6.179
|
-8.6
|
-7.694
|
-
|
-
|
-
|
-
|
Operating Margin
|
-6,418.94%
|
-8,331.56%
|
-2,978.09%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-1.95
|
-13.74
|
-2.428
|
-2.242
|
-3.968
|
-5.384
|
-4.038
|
-5.928
|
-8.409
|
-7.593
|
-
|
-
|
-
|
-
|
Net income
|
-1.95
|
-13.74
|
-2.428
|
-2.242
|
-3.968
|
-5.384
|
-4.038
|
-5.928
|
-8.409
|
-7.593
|
-
|
-
|
-
|
-
|
Net margin
|
-6,414.01%
|
-8,331.11%
|
-2,977.46%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-4.650
|
-33.60
|
-5.100
|
-2.700
|
-2.550
|
-3.000
|
-2.250
|
-3.300
|
-4.800
|
-3.940
|
-5.560
|
-5.820
|
-1.610
|
-1.740
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
3/9/22
|
4/27/22
|
8/3/22
|
11/9/22
|
3/23/23
|
5/4/23
|
8/9/23
|
11/8/23
|
2/29/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-2.91
|
-
|
-19.2
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
0.13
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
164.68%
|
-
|
-
|
Announcement Date
|
3/24/20
|
3/23/21
|
3/9/22
|
3/23/23
|
2/29/24
|
-
|
Last Close Price
1.42
USD Average target price
105
USD Spread / Average Target +7,294.36% Consensus |
1st Jan change
|
Capi.
|
---|
| -73.78% | 3.28M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|